To address the growing needs of patients with heart failure (HF), the American Heart Association (AHA) has announced the creation of the Home Health Heart Failure Certification Program.…

Omecamtiv mecarbil is associated with significant benefits for patients with severe heart failure (HF), according to new data published in JAMA Cardiology.

…

Long‐term exposure to air pollution and traffic noise is associated with an elevated risk for developing heart failure, according to new data published in the Journal of the American Heart…

Older patients hospitalized with heart failure acute decompensated heart failure (ADHF) and preserved ejection fraction (HFpEF) had poor baseline functionality, quality of life (QOL) and depression…

Remote visits for heart failure (HF) were tied to lower diagnostic testing and guideline-directed medical therapy prescription (GDMT), while teleconsults were associated with elevated 90-day…

Patients with heart failure (HF) who undergo remote pulmonary artery (PA) pressure monitoring may face a lower risk of being hospitalized, according to new data published in Current Problems in Cardiology. …

Heart failure (HF) patients who also have cirrhosis of the liver face a heightened risk of 30-day rehospitalization, according to new data published in Current Problems in Cardiology.…

Transcatheter edge-to-edge repair (TEER) with the MitraClip device provides improved outcomes for both male and female heart failure (HF) patients with secondary mitral regurgitation (SMR), according to a new…

Organ transplant recipients face a shortened lifespan after developing cancer, according to new data published in Cancer.

…

Expanded FDA labeling is poised to dramatically increase the potential heart failure (HF) patient population eligible for sacubitril/valsartan by up to 1.8 million people, according to new data published in JAMA…

Researchers have developed a new risk score capable of identifying when atrial fibrillation (AFib) patients who visit the emergency department (ED) are at an elevated risk of new-onset heart failure…

Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.…

The Heart Failure Society of America (HFSA) has published a new scientific statement focused on the treatment of COVID-19 patients with heart failure.

The statement, simultaneously published in the…

Generating premature cells that support early heart development may lead to novel therapies for heart failure in the future, according to new data published in Nature Communications.…

Myocarditis is associated with approximately 2.7 cases per 100,000 vaccinated individuals, according to a new study from the Clalit Research Institute in Israel and Harvard University. Meanwhile, the condition is associated with…

Sarpogrelate, a common antiplatelet medication, may provide additional value as a low-cost heart failure treatment, according to new findings presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific…

Left ventricular assist devices (LVADs) lead to strong outcomes among patients over the age of 75, according to new data published in the Journal of the American College of Cardiology.

“…

Empagliflozin has received FDA approval as a treatment for adult patients with heart failure with reduced ejection fraction (HFrEF).

The SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and…

Approximately one in six patients with heart failure (HF) delay medical care or go without it altogether, according to new data published in JACC: Heart Failure. More than half of those…

Heart failure patients who undergo transcatheter mitral valve repair (TMVR) and have severe secondary mitral regurgitation (SMR)…

The FDA has announced that Boston Scientific is recalling 48,000 INGENIO pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps).

The recall is due to potential issues when the devices…